

Microgenesis – SAFE Round 2025

From Fertility to Longevity: A Natural Evolution

Who we are:

Microgenesis is a biotechnology company founded by **Dr. Gabriela Gutiérrez (PhD, CONICET)** that developed a **third-generation epigenetic test** to estimate a woman's **reproductive biological age** through functional **microRNAs** obtained from a simple swab. Our mission is to help women with infertility **restore reproductive health, optimize egg quality and uterine environment**, and **extend this knowledge toward women's health and longevity**.

Traction

- 700+ women tested across 3 countries
- 500+ babies born thanks to our technology
- Active programs in Argentina, Spain, and the USA
- Ongoing clinical studies and publications

Technology

- We do **not sequence bacteria**—we interpret the **microRNAs** the body produces in dialogue with the gut and reproductive microbiota.
- We identify **hidden inflammatory phenotypes** in unexplained infertility.
- The test integrates into a **90-day nutritional and immunometabolic recovery program**.
- **Scalable model**: from fertility to longevity and menopause.

Business model

- **B2C**: Women seeking pregnancy or fertility preservation.
- **B2B**: IVF clinics and CLIA labs as strategic partners.
- **Subscription model** for reproductive and longevity health programs.

Market (TAM/SAM)

- Global fertility: **+\$35B**
- Women's longevity: **> \$70B projected by 2030**
- Initial focus: Assisted fertility—a high-CAC but highly committed segment with proven willingness to pay.